泛素特异性蛋白酶1在肿瘤中的研究进展

doi:10.16352/j.issn.1001-6325.2026.09.1277

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (9): 1277-1281.doi: 10.16352/j.issn.1001-6325.2026.09.1277

泛素特异性蛋白酶1在肿瘤中的研究进展

刘林弟¹, 刘旭妍^2*, 吕庆杰^1*

1.中国医科大学附属盛京医院病理科,辽宁沈阳 110004;
2.辽宁省健康产业集团本钢总医院病理科,辽宁本溪 117000

收稿日期:2025-08-22 修回日期:2025-11-26 出版日期:2026-09-05 发布日期:2026-08-18
通讯作者: ^*lvqjie@163.com; lxy_7169@163.com
基金资助:
国家自然科学基金(82072095);辽宁省科技计划联合计划(基金)项目-重点研发计划(2023JH2/101800019);辽宁省“兴辽英才计划”-医学名家项目(XLYC2412006)

Progress in ubiquitin-specific protease 1 of tumors

LIU Lindi¹, LIU Xuyan^2*, LYU Qingjie^1*

1. Department of Pathology, Shengjing Hospital of China Medical University, Shenyang 110004;
2. Department of Pathology, Liaoning Province Health Industry Group Bengang General Hospital, Benxi 117000, China

Received:2025-08-22 Revised:2025-11-26 Online:2026-09-05 Published:2026-08-18
Contact: ^*lvqjie@163.com; lxy_7169@163.com

摘要/Abstract

摘要： 泛素特异性蛋白酶1(USP1)是去泛素化酶家族的重要成员,通过调控关键蛋白质的稳定性参与DNA损伤修复等生物学过程。USP1在多种癌细胞中表达异常,通过影响DNA损伤修复、上皮细胞间质转化、自噬、细胞周期、线粒体裂变等生物学过程调节癌细胞的发生发展。深入解析USP1在各类癌细胞中的作用机制,为肿瘤诊断与防治以及靶向USP1的药物开发提供理论依据。

关键词: 泛素特异性蛋白酶1, 癌, 化疗耐药, DNA损伤

Abstract: Ubiquitin-specific protease 1 (USP1) is an important member of the deubiquitinase family. It participates in biological processes such as DNA damage repair by regulating the stability of key proteins. USP1 is abnormally expressed in various tumors, and its expression level is closely related to tumor initiation, progression, metastasis and prognosis. Abnormal USP1 expression in multiple cancer cell types regulates cancer cell development through affecting biological processes including DNA damage repair, epithelial-mesenchymal transition, autophagy, cell cycle and mitochondrial fission. In-depth analysis of USP1 function and mechanism involved in various cancer cells provides a theoretical basis for diagnosis, prevention and treatment, as well as the development of USP1-targeted drugs.

Key words: ubiquitin-specific protease 1, cancer, chemoresistance, DNA damage

中图分类号:

刘林弟, 刘旭妍, 吕庆杰. 泛素特异性蛋白酶1在肿瘤中的研究进展[J]. 基础医学与临床, 2026, 46(9): 1277-1281.

LIU Lindi, LIU Xuyan, LYU Qingjie. Progress in ubiquitin-specific protease 1 of tumors[J]. Basic & Clinical Medicine, 2026, 46(9): 1277-1281.

参考文献

[1] Zhao Y, Xue C, Xie Z, et al. Comprehensive analysis of ubiquitin-specific protease 1 reveals its importance in hepatocellular carcinoma[J]. Cell Prolif, 2020,10:e12908. doi: 10.1111/cpr.12908.
[2] Fujiwara T, Saito A, Suzuki M, et al. Identification and chromosomal assignment of USP1, a novel gene encoding a human ubiquitin-specific protease[J]. Genomics, 1998,54:155-158. doi: 10.1006/geno.1998.5554.
[3] Wang L, Hu T, Shen Z, et al. Inhibition of USP1 activates er stress through ubi-protein aggregation to induce autophagy and apoptosis in HCC[J]. Cell Death Dis, 2022,13:951. doi: 10.1038/s41419-022-05341-3.
[4] Bian S, Ni W, Zhou L, et al. Ubiquitin-specific protease 1 facilitates hepatocellular carcinoma progression by modulating mitochondrial fission and metabolic reprogramming via cyclin-dependent kinase 5 stabilization[J]. Cell Death Differ, 2024,31:1202-1218. doi: 10.1038/s41418-024-01342-1.
[5] Wu Z, Li C, Zhang S, et al. High interstitial fluid pressure enhances USP1-dependent KIF11 protein stability to promote hepatocellular carcinoma progression[J]. J Transl Med, 2025,23:66. doi: 10.1186/s12967-025-06124-y.
[6] Ma A, Tang M, Zhang L, et al. USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis[J]. Oncogene, 2019,38:2405-2419. doi: 10.1038/s41388-018-0590-8.
[7] Su Y, Du Y, He W. USP1-mediated deubiquitination of KDM1A promotes the malignant progression of triple-negative breast cancer[J]. J Biochem Mol Toxicol, 2024,38:e23864. doi: 10.1002/jbt.23864.
[8] Li JT, Li KY, Su Y, et al. Diet high in branched-chain amino acid promotes pdac development by USP1-mediated BCAT2 stabilization[J]. Natl Sci Rev, 2022,9:nwab212. doi: 10.1093/nsr/nwab212.
[9] Li L, Fan Z, Liu M, et al. USP1 promotes pancreatic cancer progression and autophagy by deubiquitinating ATG14[J]. J Biol Chem, 2025,301:108190. doi: 10.1016/j.jbc.2025.108190.
[10] Sun Y, Sha B, Huang W, et al. Ml323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells[J]. Apoptosis, 2022,27:545-560. doi: 10.1007/s10495-022-01736-x.
[11] Tang X, Weng R, Guo G, et al. USP10 regulates macrophage inflammation responses via stabilizing nemo in lps-induced sepsis[J]. Inflamm Res, 2023,72:1621-1632. doi: 10.1007/s00011-023-01768-2.
[12] Zhang DY, Zhu Y, Wu Q, et al. USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation[J]. Cell Death Dis, 2023,14:669. doi: 10.1038/s41419-023-06172-6.
[13] Lee JK, Chang N, Yoon Y, et al. USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance[J]. Neuro Oncol, 2016,18:37-47. doi: 10.1093/neuonc/nov091.
[14] Das DS, Das A, Ray A, et al. Blockade of deubiquitylat-ing enzyme USP1 inhibits DNA repair and triggers apoptosis in multiple myeloma cells[J]. Clin Cancer Res, 2017,23:4280-4289. doi: 10.1158/1078-0432.CCR-16-2692.
[15] Simoneau A, Engel JL, Bandi M, et al. Ubiquitinated pcna drives USP1 synthetic lethality in cancer[J]. Mol Cancer Ther, 2023,22:215-226. doi: 10.1158/1535-7163.MCT-22-0409.
[16] da Costa AA, Somuncu O, Ravindranathan R, et al. Single-stranded DNA gap accumulation is a functional biomarker for USP1 inhibitor sensitivity[J]. Cancer Res, 2024,84:3435-3446. doi: 10.1158/0008-5472.CAN-23-4007.
[17] Nespolo A, Stefenatti L, Pellarin I, et al. USP1 deubiquitinates parp1 to regulate its trapping and parylation activity[J]. Sci Adv, 2024,10:eadp6567. doi: 10.1126/sciadv.adp6567I.
[18] Cadzow L, Brenneman J, Tobin E, et al. The USP1 inhibitor KSP-4279 overcomes parp inhibitor resistance in homologous recombination-deficient tumors[J]. Cancer Res, 2024,84:3419-3434. doi: 10.1158/0008-5472.CAN-24-0293.
[19] Tyagi A, Kaushal K, Chandrasekaran AP, et al. Crispr/cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells[J]. Theranostics, 2022,12:5949-5970. doi: 10.7150/thno.72826.
[20] Woo SM, Kim S, Seo SU, et al. Inhibition of USP1 enhances anticancer drugs-induced cancer cell death through downregulation of survivin and Mir-216a-5p-mediated upregulation of DR5[J]. Cell Death Dis, 2022,13:821. doi: 10.1038/s41419-022-05271-0.
[21] Mallard HJ, Wan S, Nidhi P, et al. USP1 expression driven by ews::Fli1 transcription factor stabilizes survivin and mitigates replication stress in ewing sarcoma[J]. Mol Cancer Res,2023,21:1186-1204. doi: 10.1158/1541-7786.MCR-23-0323.
[22] Lu Z, Zhang Z, Yang M, et al. Ubiquitin-specific protease 1 inhibition sensitizes hepatocellular carcinoma cells to doxorubicin by ubiquitinated proliferating cell nuclear antigen-mediated attenuation of stemness[J]. Anticancer Drugs, 2022,33:622-631. doi: 10.1097/CAD.0000000000001311.
[23] Chen Z, Ma Y, Guo Z, et al. Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit[J]. Ann Hepatol, 2022,27:100669. doi: 10.1016/j.aohep.2022.100669.
[24] Li XY, Wu JC, Liu P, et al. Inhibition of USP1 reverses the chemotherapy resistance through destabilization of max in the relapsed/refractory b-cell lymphoma[J]. Leukemia, 2023,37:164-177. doi: 10.1038/s41375-022-01747-2.

泛素特异性蛋白酶1在肿瘤中的研究进展

Progress in ubiquitin-specific protease 1 of tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘桂举, 袁威, 吕鼎霖, 韩倩倩, 梅家转, 张浩哲. 扁蒴藤素提高人食管鳞状细胞癌耐药细胞株ECA109/DDP的顺铂敏感性[J]. 基础医学与临床, 2026, 46(9): 1200-1206.
[2]	张友梁, 任光玉, 吴嘉, 朱皓皞. LINC00339通过调控miR-15b-5p/E2F3轴促进人甲状腺癌细胞系的迁移和侵袭[J]. 基础医学与临床, 2026, 46(9): 1175-1182.
[3]	由婷婷, 唐辉, 宋东峰, 应金蓉, 白春梅. 小细胞肺癌诊疗进展[J]. 基础医学与临床, 2026, 46(8): 1149-1153.
[4]	韩超, 孔为民, 宋丹. 过表达miR-130a-3p增强人宫颈癌细胞系Caski对放化疗的敏感性[J]. 基础医学与临床, 2026, 46(8): 1103-1108.
[5]	刘获晞, 黄柏添, 赵云焘, 张家洋, 吴文梅. 过表达组蛋白去乙酰化酶4抑制人结直肠癌细胞系的增殖及侵袭[J]. 基础医学与临床, 2026, 46(8): 1051-1058.
[6]	范文怡, 陈瑜炜, 郑翠婷, 吕佳蕊, 王亚南. Pifithrin-μ抑制TSC2突变肝癌细胞株增殖[J]. 基础医学与临床, 2026, 46(8): 1059-1067.
[7]	秦子亿, 徐也婷, 邹佳铭, 马金阳, 王钰铖, 鞠瑞, 郭磊. 羧胺三唑乳清酸盐调控肿瘤相关成纤维细胞功能并重塑胰腺癌微环境[J]. 基础医学与临床, 2026, 46(8): 1068-1075.
[8]	葛郁平, 高鑫, 孙昭, 周建凤. 恩沃利单抗治疗POLE突变型局部进展期直肠癌临床完全缓解1例[J]. 基础医学与临床, 2026, 46(8): 1126-1129.
[9]	董泽耀, 林淑瑜, 戴立. 自噬抑制剂Spautin-1增加人胰腺癌细胞系PaTu 8988t凋亡率[J]. 基础医学与临床, 2026, 46(7): 932-938.
[10]	陈子然, 黄容, 卢艳, 李凯, 宋伟. 基于胆管癌类器官的吉西他滨耐药基因特征构建与验证[J]. 基础医学与临床, 2026, 46(7): 904-912.
[11]	伍娅妮, 代伽茵, 杨振丽, 侯昱宏, 卞晓翠, 刘玉琴. 携带KRAS G12C突变及Cas9稳定表达的靶向药不同敏感性胰腺癌细胞株的建立[J]. 基础医学与临床, 2026, 46(7): 965-974.
[12]	甄宏楠, 王方, 肖嘉宁, 姜斐, 张园, 沈晶. 基线营养状态与宫颈癌放射治疗导致的慢性不良反应的关系[J]. 基础医学与临床, 2026, 46(7): 998-1003.
[13]	陈伟鑫, 时雨, 王颖轶, 刘洪生, 李太生. 非小细胞肺癌早晚期患者外周血淋巴细胞亚群的免疫特征分析[J]. 基础医学与临床, 2026, 46(6): 823-829.
[14]	李书翔, 潘玮瑄, 保永莉, 夏婉娉, 李雪媛, 郑永昌, 陈阳. 肝细胞癌肿瘤边界代谢空间异质性研究[J]. 基础医学与临床, 2026, 46(6): 815-822.
[15]	张帅, 王腾祺, 田永静, 庞健, 孙海滨, 雷馨文. KRT15调节胃癌免疫微环境并抑制恶性表型[J]. 基础医学与临床, 2026, 46(5): 658-665.